<SEC-DOCUMENT>0001193125-25-273269.txt : 20251110
<SEC-HEADER>0001193125-25-273269.hdr.sgml : 20251110
<ACCEPTANCE-DATETIME>20251110073253
ACCESSION NUMBER:		0001193125-25-273269
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20251106
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251110
DATE AS OF CHANGE:		20251110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lyell Immunopharma, Inc.
		CENTRAL INDEX KEY:			0001806952
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				833006753
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40502
		FILM NUMBER:		251464357

	BUSINESS ADDRESS:	
		STREET 1:		201 HASKINS WAY
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650 695-0677

	MAIL ADDRESS:	
		STREET 1:		201 HASKINS WAY
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d57756d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lyel="http://www.lyell.com/20251106" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-318">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-11-06_to_2025-11-06">0001806952</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="lyel-20251106.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-11-06_to_2025-11-06"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-06</xbrli:startDate> <xbrli:endDate>2025-11-06</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-329">8-K</ix:nonNumeric></span></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-11-06_to_2025-11-06" format="ixt:datemonthdayyearen" id="ixv-330">November&#160;6, 2025</ix:nonNumeric></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-331">Lyell Immunopharma, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-11-06_to_2025-11-06" format="ixt-sec:stateprovnameen" id="ixv-332">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-333">001-40502</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-334">83-1300510</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:33%"/>
<td style="vertical-align:bottom"/>
<td style="width:31%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-335">201 Haskins Way</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-336">South San Francisco</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-11-06_to_2025-11-06" format="ixt-sec:stateprovnameen" id="ixv-337">California</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-338">94080</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <span style="white-space:nowrap"><span style="white-space:nowrap"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-339">650</ix:nonNumeric>-<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-340">695-0677</ix:nonNumeric></span></span></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-11-06_to_2025-11-06" format="ixt-sec:boolballotbox" id="ixv-341">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-11-06_to_2025-11-06" format="ixt-sec:boolballotbox" id="ixv-342">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-11-06_to_2025-11-06" format="ixt-sec:boolballotbox" id="ixv-343">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-11-06_to_2025-11-06" format="ixt-sec:boolballotbox" id="ixv-344">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title&#160;of&#160;each&#160;class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name&#160;of&#160;each&#160;exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on&#160;which&#160;registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-345">Common Stock, $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-346">LYEL</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-11-06_to_2025-11-06" format="ixt-sec:exchnameen" id="ixv-347">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#8201;240.12b-2</span> of this chapter).</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-11-06_to_2025-11-06" format="ixt-sec:boolballotbox" id="ixv-348">&#9744;</ix:nonNumeric></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;6, 2025 (the &#8220;Effective Date&#8221;), Lyell Immunopharma, Inc., a Delaware corporation (the &#8220;Company&#8221;), entered into an Exclusive License Agreement (the &#8220;License Agreement&#8221;) with Innovative Cellular Therapeutics Holdings Limited, a Cayman Island exempted company incorporated with limited liability (&#8220;ICT Holdings&#8221;), and Innovative Cellular Therapeutics, Inc., a Delaware corporation (&#8220;ICT&#8221; and together with ICT Holdings, the &#8220;ICT Group&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the License Agreement, (i)&#160;the ICT Group granted the Company an exclusive license to research, develop, manufacture, commercialize and otherwise exploit certain product candidates and products worldwide except in mainland China, Taiwan, Macau and Hong Kong and (ii)&#160;the Company will (a)&#160;pay, or cause to be paid, to ICT Holdings $40&#160;million in cash and (b)&#160;issue to ICT Holdings 1.9&#160;million shares of the Company&#8217;s common stock, par value $0.0001 (&#8220;Company Common Stock&#8221;). Contingent consideration payable following the Effective Date includes (i)&#160;a potential $30&#160;million clinical milestone payment, up to $115&#160;million upon achievement of certain late-stage regulatory milestones and up to $675&#160;million in commercial sales milestones, (ii)&#160;up to an additional 1.85&#160;million shares of Company Common Stock upon achievement of certain clinical and regulatory milestones and (iii)&#160;tiered royalties ranging from <span style="white-space:nowrap">mid-single</span> digits up to 10% on annual net sales in the United States and low to <span style="white-space:nowrap">mid-single-digit</span> royalties on annual net sales in other countries within the licensed territory. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The License Agreement includes customary representations, warranties and covenants, including, but not limited to, covenants by the Company and the ICT Group to conduct the research, development, manufacture, commercialization and other exploitation of the product candidates and products, and their other obligations under the License Agreement, in compliance with the terms of the License Agreement and all other applicable laws and marketing approvals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The License Agreement may be terminated, among other circumstances, (i)&#160;by either party for uncured material breach, (ii)&#160;by either party due to the insolvency of the other party, (iii)&#160;by the Company for safety or regulatory reasons or (iv)&#160;by the Company on a <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-product</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis in its sole discretion after providing certain notice. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The License Agreement (and any right or obligation thereunder) may not be assigned without the prior written consent of the other party, except to an affiliate or third party that acquires the business of the assigning party by way of a merger or sale of assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the License Agreement, the Company also entered into a Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;) with ICT Holdings. Pursuant to the Registration Rights Agreement, the Company agreed to provide ICT Holdings certain registration rights in connection with the shares of Company Common Stock issuable under the License Agreement, including to file shelf registration statements permitting the resale of such shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the License Agreement and the Registration Rights Agreement is not intended to be complete and is qualified in its entirety by reference to the full text of the License Agreement and the Registration Rights Agreement. Copies of both the License Agreement and the Registration Rights Agreement will be filed as exhibits to the Company&#8217;s Annual Report on <span style="white-space:nowrap">Form&#160;10-K</span> for the fiscal year ending December&#160;31, 2025. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;3.02.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Unregistered Sale of Equity Securities. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information contained above under Item 1.01, to the extent required by Item 3.02 of <span style="white-space:nowrap">Form&#160;8-K,</span> is hereby incorporated by reference herein. The offer and sale of the securities issuable under the License Agreement are being made in reliance on the exemption afforded by Section&#160;4(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and corresponding provisions of state securities or &#8220;blue sky&#8221; laws. The securities issuable under the License Agreement have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the &#8220;SEC&#8221;) or an applicable exemption from the registration requirements. The issuance and sale of the securities issuable under the License Agreement did not involve a public offering and was made without general solicitation or general advertising. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this Current Report on Form <span style="white-space:nowrap">8-K</span> nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Company Common Stock or other securities of the Company. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;7.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2025, the Company issued a press release announcing the execution of the License Agreement. Pursuant to Regulation FD, a copy of the press release is furnished with this Current Report on Form <span style="white-space:nowrap">8-K</span> as Exhibit 99.1 and incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as expressly set forth by specific reference in such filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this Current Report on Form <span style="white-space:nowrap">8-K</span> include, but are not limited to, statements regarding: the anticipated benefits of the proposed license; the Company&#8217;s anticipated progress, business plans, business strategy and clinical trials; the achievement of future development milestones; the Company&#8217;s advancement of its pipeline and its research, development and clinical capabilities; and other statements that are not historical fact. These statements are based on the Company&#8217;s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: the inability to recognize the anticipated benefits of the license described herein; the effects of macroeconomic conditions, including any geopolitical instability and actual or perceived changes in interest rates and economic inflation; the Company&#8217;s or the ICT Group&#8217;s ability to initiate or progress clinical trials on the anticipated timelines, if at all; the sufficiency of the Company&#8217;s capital resources and need for additional capital to achieve its goals; and other risks, including those described under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2024, filed with the SEC on March&#160;11, 2025, and the Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the quarter ended June&#160;30, 2025, filed with the SEC on August&#160;12, 2025. Forward-looking statements contained in this Current Report on Form <span style="white-space:nowrap">8-K</span> are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br/>Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description&#160;of&#160;Exhibit</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d57756dex991.htm">Press Release, dated November&#160;10, 2025</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Lyell&#160;Immunopharma,&#160;Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: November&#160;10, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lynn Seely, M.D.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Lynn Seely, M.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d57756dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR <FONT STYLE="white-space:nowrap">T-Cell</FONT> Product Candidate in Clinical
Development for Metastatic Colorectal Cancer </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile
at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 clinical trial </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">LYL273 is a <FONT STYLE="white-space:nowrap">GCC-targeted</FONT> CAR
<FONT STYLE="white-space:nowrap">T-cell</FONT> product candidate armed with enhancements designed to improve CAR <FONT STYLE="white-space:nowrap">T-cell</FONT> expansion and cancer cell killing </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lyell management will host an investor webcast at 8:30 AM ET today </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SOUTH SAN FRANCISCO, Calif., November&nbsp;10, 2025 &#8212; Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation
chimeric antigen receptor (CAR) <FONT STYLE="white-space:nowrap">T-cell</FONT> therapies for patients with cancer, today announced it has strengthened its solid tumor pipeline by acquiring global rights to LYL273 (formerly GCC19CART), a novel
autologous guanylyl <FONT STYLE="white-space:nowrap">cyclase-C</FONT> (GCC)-targeted CAR <FONT STYLE="white-space:nowrap">T-cell</FONT> product candidate for the treatment of metastatic colorectal cancer (mCRC) and other <FONT
STYLE="white-space:nowrap">GCC-expressing</FONT> cancers, from Innovative Cellular Therapeutics (ICT). Patients with refractory mCRC treated with LYL273 in a Phase 1 clinical trial conducted in the United States (U.S.) achieved a 67% overall
response rate and an 83% disease control rate (complete and partial response plus stable disease) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with a manageable safety profile at the highest dose level studied to date. LYL273 is a <FONT
STYLE="white-space:nowrap">GCC-targeted</FONT> CAR <FONT STYLE="white-space:nowrap">T-cell</FONT> product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR
<FONT STYLE="white-space:nowrap">T-cell</FONT> expansion, immune cell infiltration and cancer cell killing in the hostile solid tumor microenvironment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;We rarely see such deep and durable responses in colorectal cancer patients treated with multiple prior lines of chemotherapy.&nbsp;The outcomes in
this initial cohort of heavily <FONT STYLE="white-space:nowrap">pre-treated</FONT> patients are very encouraging,&#8221; said Benjamin L. Schlechter, MD, Senior Physician in the Gastrointestinal Cancer Center, Dana-Farber Cancer Institute and
Assistant Professor of Medicine at Harvard Medical School, Boston, MA, and lead investigator in the Phase 1 clinical trial. &#8220;Patients with metastatic colorectal cancer have a tremendous need for innovations like LYL273, and I look forward to
partnering with the Lyell team as we work to rapidly deliver on the potential of this innovative cellular therapy for patients with advanced colorectal cancer.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;The ability to treat solid tumors with an acceptable safety profile has become the holy grail for CAR <FONT STYLE="white-space:nowrap">T-cell</FONT>
therapy for cancer,&#8221; said Richard Klausner, MD, Lyell <FONT STYLE="white-space:nowrap">co-founder</FONT> and Board Chairman, former Director of the National Cancer Institute and <FONT STYLE="white-space:nowrap">co-founder</FONT> and former
Director of Juno Therapeutics. &#8220;These impressive early results suggest we may be on the path to finally breaking the barrier for solid cancer.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide, and the incidence of colorectal cancer is rising in people younger than 55
years old. Approximately 53,000 people are expected to die from CRC in the U.S. in 2025. With approved therapies, only six percent of patients with mCRC in the third- or later-line setting achieve partial or complete responses to their next line of
therapy, and median overall survival is generally less than 12 months. GCC is a receptor that plays a key role in the regulation of intestinal electrolyte homeostasis. It is expressed on more than 95% of colorectal cancers and a majority of
pancreatic adenocarcinomas. Its expression in healthy tissue is limited to the gastrointestinal tract, where it is sequestered by tight junctions from the circulation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Phase 1 Clinical Trial Data </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dose-dependent clinical activity in 12 patients enrolled in a Phase 1 clinical trial in the U.S. are reported as of an October&nbsp;28, 2025 data cutoff date.
Six patients were treated at Dose Level&nbsp;1 (1 x 10<SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;CAR T cells/kg) and six patients were treated at Dose Level&nbsp;2 (2 x
10<SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;CAR T cells/kg). All patients received a single dose of lymphodepleting chemotherapy on Day <FONT STYLE="white-space:nowrap">-3,</FONT> including cyclophosphamide, 300 mg/m<SUP
STYLE="font-size:75%; vertical-align:top">2</SUP>, and fludarabine, 30 mg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>. RECIST 1.1 classification of imaging results is per local site review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Across both dose levels, the overall response rate was 50% (6 of 12 patients) and the disease control rate was 83%. At the highest dose tested, Dose
Level&nbsp;2, the overall response rate was 67% (4 of 6 patients), including one patient with a pathological complete response, one patient with complete reduction in tumor volume of the target lesions (100% partial response), and two additional
patients with confirmed partial responses. For patients treated at Dose Level&nbsp;2, the disease control rate was 83%, and the median progression-free survival was 7.8 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The incidence and severity of treatment-related adverse events were higher at Dose Level&nbsp;2 than at Dose Level&nbsp;1. The most common treatment-related
adverse events at Dose Level&nbsp;2 were cytokine release syndrome in 83% (5/6) of patients (Grade 1, 67%; Grade 2, 17%) and diarrhea in 83% (5/6) of patients (Grade 1, 33%; Grade 2, 33%; Grade 3, 17%). Immune effector cell-associated neurotoxicity
syndrome occurred in 33% (2/6) of patients (Grade 2, 17%; Grade 3, 17%) and resolved rapidly with treatment. One patient experienced a dose-limiting toxicity at Dose Level&nbsp;2, including Grade 3 diarrhea, Grade 4 enterocolitis and death from
fungal sepsis 48 days post-infusion.&nbsp;No Grade 3 or higher diarrhea has occurred in the last three patients treated since establishing an optimized management protocol for diarrhea, including prophylaxis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Lyell was founded to realize the full potential of cell therapy for solid tumors, which make up more than 90% of all cancers. We believe LYL273 has the
potential to be a transformational advance in the treatment of colorectal cancer, an area of tremendous unmet need,&#8221; said Lynn Seely, MD, Lyell&#8217;s President and Chief Executive Officer. &#8220;We look forward to leveraging our expertise
in <FONT STYLE="white-space:nowrap">T-cell</FONT> biology and CAR <FONT STYLE="white-space:nowrap">T-cell</FONT> clinical development to rapidly progress this program, as well as our two pivotal clinical trials evaluating <FONT
STYLE="white-space:nowrap">ronde-cel</FONT> for patients with relapsed or refractory large <FONT STYLE="white-space:nowrap">B-cell</FONT> lymphoma.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LYL273 was granted Fast Track designation for the treatment of mCRC by the U.S. Food and Drug Administration. The Phase 1 clinical trial is continuing to
enroll patients with refractory mCRC to determine the recommended Phase 2 dose. The next data update from this clinical trial is expected in the first half of 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> was initially demonstrated in an
investigator-sponsored clinical trial conducted in China. Data from this clinical trial in 15 patients with mCRC were published in <I>JAMA Oncology</I> (September 2024). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Details of the Transaction </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the
definitive license agreement, Lyell will receive exclusive global rights, outside of mainland China, Hong Kong, Macau and Taiwan, to research, develop, manufacture and commercialize LYL273. ICT will receive an upfront payment of $40&nbsp;million and
1.9&nbsp;million shares of Lyell common stock. ICT is also eligible to receive additional cash and equity consideration, as well as royalties on future net sales. Additional cash consideration consists of a potential $30&nbsp;million clinical
milestone, up to $115&nbsp;million in late-stage regulatory milestones and up to $675&nbsp;million in commercial sales milestones. Additional equity consideration consists of up to 1.85&nbsp;million shares of Lyell common stock upon achievement of
certain clinical and late-stage regulatory milestones. Tiered royalties range from <FONT STYLE="white-space:nowrap">mid-single</FONT> digits up to 10% on annual net sales in the U.S. and low to
<FONT STYLE="white-space:nowrap">mid-single-digit</FONT> royalties on annual net sales in other countries within the licensed territory. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the close of the transaction, Lyell expects its cash will be adequate to fund operations into 2027
through data and progress updates from the rondecabtagene autoleucel <FONT STYLE="white-space:nowrap">(ronde-cel)</FONT> clinical program for patients with large <FONT STYLE="white-space:nowrap">B-cell</FONT> lymphoma and additional clinical data
from the Phase 1 clinical trial of LYL273. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction will have a modest impact on operating expenses for 2025. As a result of continued prudent
expense management, Lyell now expects net cash use in 2025 to be between $155&nbsp;million and $160&nbsp;million, excluding the $40&nbsp;million upfront payment from the transaction, below its previous net cash use guidance of between
$175&nbsp;million and $185&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP served as legal counsel to Lyell. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call Details </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lyell&#8217;s management will
host an investor conference call and webcast beginning at 8:30 AM ET today. The webcast can be accessed <U>here</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A replay of the event and
presentation materials will be archived on the Investor page of the Lyell Website following the end of the event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements
expressed or implied in this press release include, but are not limited to, statements regarding: the potential clinical benefits and therapeutic potential of LYL273 and <FONT STYLE="white-space:nowrap">ronde-cel;</FONT> statements made by our Chief
Executive Officer and others; expectations around enrollment for, and the next data update from, the Phase 1 clinical trial of LYL273; Lyell&#8217;s expectation that its cash will be adequate to fund operations into 2027 and through data and
progress updates from the <FONT STYLE="white-space:nowrap">ronde-cel</FONT> clinical program and additional clinical data from the Phase 1 clinical trial of LYL273; Lyell&#8217;s estimated 2025 net cash use; Lyell&#8217;s ability to rapidly move
forward the development of LYL273; and other statements that are not historical fact. These statements are based on Lyell&#8217;s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and
inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are
not limited to, risks and uncertainties related to: Lyell&#8217;s limited experience as a company in initiating and conducting clinical trials, and lack of experience in completing clinical trials; the nonclinical profiles of Lyell&#8217;s product
candidates or technology not translating in clinical trials; the potential for results from clinical trials to differ from nonclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side
effects associated with Lyell&#8217;s product candidates; Lyell&#8217;s ability to submit planned INDs or initiate or progress clinical trials on the anticipated timelines, if at all; RMAT and Fast Track designations may not actually lead to faster
development, regulatory review or approval process, and do not assure ultimate FDA approval; the significant uncertainty associated with Lyell&#8217;s product candidates ever receiving any regulatory approvals; Lyell&#8217;s ability to obtain,
maintain or protect intellectual property rights related to its product candidates; the complexity of manufacturing cellular therapies and Lyell&#8217;s ability to manufacture and supply its product candidates for its clinical trials; implementation
of Lyell&#8217;s strategic plans for its business and product candidates; Lyell&#8217;s realization of the expected benefits of its strategic plans for its business and product candidates, including the license of LYL273; the potential reduction of
Lyell&#8217;s cash </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
resources and fluctuations in Lyell&#8217;s operating results and financial condition as a result of Lyell&#8217;s milestone, royalty and success payment obligations for LYL273; the sufficiency
of Lyell&#8217;s capital resources and need for additional capital to achieve its goals; the effects of macroeconomic conditions, including the effects of disruption between the U.S. and its trading partners due to tariffs or other policies, and any
geopolitical instability; potential changes to U.S. drug pricing, including the potential for &#8220;most-favored nations&#8221; pricing limitations; other risks, including general economic conditions and regulatory developments, not within
Lyell&#8217;s control; and other risks, including those described under the heading &#8220;Risk Factors&#8221; in Lyell&#8217;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2024,
filed with the Securities and Exchange Commission on March&nbsp;11, 2025 and in Lyell&#8217;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2025, previously filed with the Securities and
Exchange Commission on August&nbsp;12, 2025. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ellen Rose </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President, Communications and Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>erose@lyell.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lyel-20251106.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/10/2025 5:31:15 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:lyel="http://www.lyell.com/20251106"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.lyell.com/20251106"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyel-20251106_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyel-20251106_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>lyel-20251106_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/10/2025 5:31:15 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>lyel-20251106_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/10/2025 5:31:15 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="lyel-20251106.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001806952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  06,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lyell Immunopharma, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1300510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">201 Haskins Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">695-0677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LYEL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d57756d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d57756d8k.htm">d57756d8k.htm</File>
    <File>lyel-20251106.xsd</File>
    <File>lyel-20251106_lab.xml</File>
    <File>lyel-20251106_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d57756d8k.htm": {
   "nsprefix": "lyel",
   "nsuri": "http://www.lyell.com/20251106",
   "dts": {
    "inline": {
     "local": [
      "d57756d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "lyel-20251106.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "lyel-20251106_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lyel-20251106_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-11-06_to_2025-11-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d57756d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-11-06_to_2025-11-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d57756d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.lyell.com//20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001193125-25-273269-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-273269-xbrl.zip
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MFT>@YL#9N:32H7^17UT!/C4X12ZX1>0+#6Y9N!0Y+^7 ]3P'?5I&!C-BJW(
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MV7G/[[[G=PORN_O5>N-[SN]^\S(;\?I&W7;!\(-^2>N@;R"W>Z/\YN2^?E6
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M<X%8V7L-14:\1@E6&WA6E@4R^M24N9B66)]H'CVN9S /(B3V[L"KNHFQMZI
M_#7Q<#4 TZ(1=L%2R()-W$P>1B*;\>!RL,4!U=#B.QG:K4<2"&(Q0%>.5?32
MV 'SCIAD)H:58;$P)T5ZB%Q&,A,CWEQ50I)<;)X-1EM ._?B)\AE]? IQ2<Y
MA/_[0!*0'JV(!5:T$)\339^NH#YL:I, %I2%T0+/+8'(=JN!(BU.O!](BDWR
MCDBY.U.9%21!-4:*B@LVR0C3/;\E4BSPI;_C]$9&I:NY,H@)#4CL*S;;$9DM
M)+X\A<>/MD0/I22OP@/053P9N6Z+5<3PZ):OP0S_N<4ZG."V>##LO>9QO7GY
M7&\7GA!S,"_,-7ERIB+>E'O Q1?#F0I==# , J:RT$(G6-K"U<;WX0YG;91*
M:!_JD2?60694<J,SDY!';HN_G0V@Z+^W>_0[&3)6:2YR!9G*8(:U4BDK$989
M&Y WUYQ46(T.50!N.&)<1H6&Z6,[-32DN)I3H EFJ-!L!)]OVXP$EQ>F+. J
M/$6[5<PT_:(+ZZXSDW&,FBEY UT>MR>81=<)4QF5%Q+*"OCR'$85&"B(19QV
M>#%Z1W 5;,D;E?R)14O$^;:X"F:1"F8%I90/PXZX4@EI\VDVSW6@&1#PIKY#
M\,Q0GB& %#I9$!66@.J((=RQ^U9F8[IFOSI#F:J+TH:&=JL/0T8D0#3^!$>%
M66,:Z/Q!A9@H8;=]+[,;F87V&N: <,9$'?$&%D46^:%O"U>8?.B0BIY*2K-.
MRO4!<5LX6VB&V0<SPDS"@23M.,PUI"27*.S\A.>R01T6@UV_5BZ*6-'.1&3,
M-=UW2YH4IMVBH BH0!["\Y*@%I(42L8"2?M6B5N379/O4MX/80(A$C5V$44Q
MWY^: H*3M6#)G/54J27PJ<59W1K48+$+!8YE3;>]:7POAR1GD&,=:81L*,QF
M7(\57F+$F8! U+H03TAGK,B?7,3!BDTSJ2-6_<M#,GGD8ND<Q&KXS*4.9K2A
MOT:RS!/O+78;'T<]ICL!3 M5YKV53.6-H0$',ZF!2&'=%FZ)H:;]L<Y!REVP
MJ2T\KN%67SNWG:O=JD_V"^!Q YU4?H.+<"M**Y2-8'%*$BS$)\1 Y/=R.J5,
M"S..@4G'JK):2>9NQ(0B!A[@NHS\@+X<RRS3T(=6W&[_]S;(P2H.9!@([R(!
M<T5 BH,-R1Q@XQ4'>'MO"+N=Y>2X47B+0M/Z/SVH426$B+[V[I5),'RF<Y<P
M4V4HA\RQ15-%'@R[/SAHM^988J23*-P6_11F?Z=C1'NLX<%^9W=WUS]'P1XI
M6S':(UBCE46>A!L]^B,^#;]33;0M?F?G2ADAA(M*HX,]HQRI[PB>!0XT-X-(
M7!L4,2@+NX(2'^3*NEQ6Y*HH2"\'+2LX2#[E8>(BUY+SSY3.N)SB_(DI*T^T
MRQDC$Q UZ!C.O,QN-  CK:&MO\BL(EBE7;G>GHBQXS.8+K":Q755*88["@!2
M.:>KUPKV:R+E]<G4%"&4X0WTKN4YX*N 4->\H#@3*Z0BB42V+<X*&M]!-"PE
MGD3T4E:0UP?/UFY^7A&O?YJ,(B!I#,054!2D^A%V8P*9(2/"1GF6O X#(2U
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M+0E#B9_3U28E@17R:<LALEN#M!IJBZ(IVS;H5)-,-#=LEA]'\GUKUA3_ZV)
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MGMJS%K$)B:G4,30NR#7=+L(Z:.>Y9T@+9_N8?=O;(V[7%HD,?HG'RTJJY@"
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M;#AW?,=36Z6L?U)_+=?V[0'B:I##N*E+%E2U<^W[.NM6:O'J1_Y _,C+,:R
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MOUNXX\\G*L,J_%?$_'E O=F=SR?W0Q7LS<?A'[C(?[3N?P%02P,$%     @
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M9$;U(IDEGX.%-='FW$Z7"A5&>'6,^T+!I(>[3GBJ +H$TBJAC;X-BP3KYC%
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M><>UVM*_=R+?1;/?OJ#V_ =02P,$%     @ &CQJ6Y%[TK^O!   =2H  !4
M  !L>65L+3(P,C4Q,3 V7W!R92YX;6S5FEV/XC84AN]7VO_@IC>MU! "RVX'
M#;.BS,P*=3X0P[95;U8F.8!5QT:V&>#?]SC@BD"8A>FVBKG@P_%[_)[S&).8
M7'Y<99P\@]),BDX0U^H! 9'(E(EI)UCHD.J$L8!H0T5*N130"=:@@X]7;]]<
M?A>&Y/JV_T!",C-FKMM1M%PN:^F$"2WYPF!(74MD%I$P=/U[H\_DM\UP;3($
M#E0#:;3B!OEEP7C:;M0;K?J'1J,6[XH44!N-I-1 F\1Q%-<CVY.TVLVX';?(
MX)[<4&U "3)B&>QJY7RMV'1FR _)CR0774LA@'-8DULFJ$@8Y>3)&?Z)]$52
M(UW.R=#*-+K4H)XAK6VC<B;^:MNGL?5.WKXA^, R"IVW=@);C&TM5F/%:U)-
MT6V]&3E1L*M9'8B6S5P27UQ<1/G18G_-RGKC ''TQ_W=4S*#C(:( )$E>T.A
MF]3\H]XUUXHV!UU_S=HZCW0GD[SV)Z1%CO:PGT+7+;1-8=P(FW%MI=/@R@ZY
MJ:J2'(8P(?;U\[!?&).OD5D^G7+T<5Q_'QFZDD)FZ\@*HFN9+#(0QKUV17HC
M##/KOIA(E>5I!"2O:'NF8-();,S01;-FOA]BH"_G!#+K.7XG-,OF' (2[20S
M5SAQA,E[WV%#00 K R*%U(6Q"?P7Z5YM>&XGK4P*Z;MO;0Y+0U*;RN<H!9:/
M:-_DM<GK@A^^]"0N%-VQ-HHFII@_M[-$*M?(Z1AX)R@11=_24!?33FWJMYQ.
M3S6T)RH:VF7654DA)%6)"X=O#X 59_RV1S2G"N.%R0P7-Z>>*)F5%F<[FBPU
M*E4*JA/@THC?](#,%9,*86-+0!8:O<BY=4VY/0834 K2NTW:1UWF%G'5U)#W
M_,9X-K.QAQDHROLXVU>_POI43$?$U<5UQ+##UO0&FUM/1EC&4VD5-=6%5/3I
MV+2\8S, ](K+?7J-9T3G0MH35Y_6GF&'[;TWV#9KPQ"FS"8JS /-3J96KJTN
MM'*_CMD'SYCAQ8!4<ZGRTCYAA:$G%[C$KWLR/1/A5T)5G>A7[#O /WL&^)9Q
M>%AD8U#GT=S551W=KE?'Z<(S3B.ZZJ=8!C9AFPO2UT [&J3J!(\:W^)LUCW#
MV4U3+++>ON#E,<3GH2P-4'6,I:8=PMA/A#U\^ZA&<BE>!7!7[@F^7<L.GF]7
MY=M4\M_Q1S50\IG9W<+7$#R(X0G& ]^.I3^7ZH5\!E(;RO]D\_-/3<LC>,)Q
MS[6C^,X;BG8]Z2J@YW K:JI+JNC3L?%GP\7^_<$',RG.O$@XU%67T:%7Q\F?
M'9;?T9\!T9-9MA#;<V1]*JPCXNH2.V+88?-GD^5)<I8PP\3T'G^,%;/63F-6
MIJPNL#*WCI8_.R8#!7;* 9XMY9OH]A],]3B9G+XLOA2ANO1><NTH^K.?LI=-
M7^L%J'_/LB2.-T1+O&^YOO-G8^4)DH6U&#?&(V;XR:>2A[KJ<COTZCCYLWLR
M4M3>7O6TSL;RY)^[/5%U">T9=7C\V1]Q4^QFE<RHF,(Y_]65:ZL+J]RO8^;;
M/LA-!FJ*<^^3DDLSP_5]3L69]YL<"5%=@B_:=B#_AZV0R^B@-'?88.^7W!RQ
M3_;N/VSY&U!+ 0(4 Q0    ( !H\:EOEN+7A_Q@  $&/   -
M  "  0    !D-3<W-39D.&LN:'1M4$L! A0#%     @ &CQJ6QM^_>;6%P
MNTX  !               ( !*AD  &0U-S<U-F1E>#DY,2YH=&U02P$"% ,4
M    "  :/&I;:R@E,38#  !""P  $0              @ $N,0  ;'EE;"TR
M,#(U,3$P-BYX<V102P$"% ,4    "  :/&I;+X<U8UL&  "]0P  %0
M        @ &3-   ;'EE;"TR,#(U,3$P-E]L86(N>&UL4$L! A0#%     @
M&CQJ6Y%[TK^O!   =2H  !4              ( !(3L  &QY96PM,C R-3$Q
@,#9?<')E+GAM;%!+!08     !0 % #X!   #0      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>d57756d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lyel-20251106.xsd" xlink:type="simple"/>
    <context id="duration_2025-11-06_to_2025-11-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <startDate>2025-11-06</startDate>
            <endDate>2025-11-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-318">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-11-06_to_2025-11-06"
      id="Hidden_dei_EntityCentralIndexKey">0001806952</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-329">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-330">2025-11-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-331">Lyell Immunopharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-332">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-333">001-40502</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-334">83-1300510</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-335">201 Haskins Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-336">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-337">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-338">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-339">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-340">695-0677</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-341">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-342">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-343">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-344">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-345">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-346">LYEL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-347">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-11-06_to_2025-11-06" id="ixv-348">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
